H.C. Wainwright raised the firm’s price target on Aquestive Therapeutics to $9 from $7 and keeps a Buy rating on the shares. The analyst says Anaphylm is “poised to take pole position” in the epinephrine product market segment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AQST:
- Aquestive Therapeutics price target raised to $10 from $8 at JMP Securities
- Aquestive Therapeutics’ Anaphylm meets endpoints in Phase 3 allergy study
- Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
- Aquestive Therapeutics price target raised to $7 from $6 at H.C. Wainwright
- Aquestive Therapeutics price target raised to $8 from $3 at Lake Street